Paratek Receives FDA Affirmation for Design of Proposed Omadacycline Oral-Only Skin Infection Phase 3 Study: Opportunity to Accelerate Access to Broader Oral-Only Markets, Potential To Include Oral-Only Study In Proj. NDA In 1H 2018